

A service of the U.S. National Library of Medicine  
and the National Institutes of Health

My NCBI [?] [Sign in] [Register]

All Databases PubMed Medline Epubs Genome Structure OMIM PLoS Bookshelf Books

Search **PubMed** for **desmoteplase clot** **Go** **Clear**

Advanced Search

Save Search

Limits Preview/Index History Clipboard Details

Display **Summary** Show **20** Sort By  Send to

Alt: **10** **Preview**

Items 1 - 10 of 10

One page.

- 1 Management of delayed edema formation after fibrinolytic therapy for intracerebral hemorrhages: preliminary experimental data.  
Rohde V, Uzma N, Thies R, Samadani U.  
Acta Neurochir Suppl 2008;105:101-4.  
PMID: 18069146 [PubMed - in process]  
Cited 2008 Apr 10.
- 2 Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies.  
Aidhathia RM, Hatcher JF.  
CNS Neurol Disord Drug Targets 2008 Jun;7(3):243-53. Review.  
PMID: 18673936 [PubMed - in process for MEDLINE]  
Cited 2008 Apr 10.
- 3 Desmoteplase-mediated plasminogen activation and clot lysis are inhibited by the lysine analogue tranexamsäure.  
Niego B, Horvath A, Coughlin PB, Pugsley MK, Medcalf RL.  
Blood Coagul Fibrinolysis 2008 Jun;19(4):322-4. No abstract available.  
PMID: 18466654 [PubMed - in process for MEDLINE]  
Cited 2008 Apr 10.
- 4 Advances in revascularization for acute ischemic stroke treatment.  
Schumacher HC, Gupta R, Higashida RT, Meyers PM.  
Expert Rev Neurother 2008 Mar;8(2):189-201. Review.  
PMID: 18523459 [PubMed - in process for MEDLINE]  
Cited 2008 Apr 10.
- 5 P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1.  
Dong N, Da Cunha V, Citkowitz A, Wu F, Vincelette J, Larsen B, Wang YX, Ruan C, Dole WP, Morser J, Wu Q, Pan J.  
Thromb Haemost 2004 Nov;82(5):956-65.  
PMID: 15542881 [PubMed - in process for MEDLINE]  
Cited 2008 Apr 10.
- 6 Vampire bats yield potent clot buster for ischemic stroke.  
Grandjean C, McMullen PC, Newswander G.  
J Cardiovasc Nurs 2004 Nov-Dec;19(6):417-20. Review.  
PMID: 15523954 [PubMed - in process for MEDLINE]  
Cited 2008 Apr 10.
- 7 Vampire bat plasminogen activator (SPA-alpha-1) (desmoteplase), a thrombolytic drug optimized by natural selection.  
Schleuning WD.  
Haemostas 2001 May-Dec;31(3-6):118-22. Review.  
PMID: 11810124 [PubMed - in process for MEDLINE]  
Cited 2008 Apr 10.
- 8 Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.  
Colucci M, D'Aprile AM, Italia A, Gesele P, Morser J, Semeraro N.  
Thromb Haemost 2001 Apr;85(4):661-6.  
PMID: 11941602 [PubMed - in process for MEDLINE]  
Cited 2008 Apr 10.
- 9 Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.

## Recent Activity

Turn Off Clear

Vampire bat plasminogen activator (SPA-alpha-1) (desmoteplase), a thrombolytic drug optimiz...  
desmoteplase clot (10)  
desmoteplase treatment st... (20)  
desmoteplase treatment st... (25)  
desmoteplase treatment (47) Published

Sakharov DV, Barrert-Bergshoeff M, Hekkenberg RT, Rijken DC.

*Thromb Haemost*. 1999 Apr;81(4):605-12.

PMID: 10235448 [PubMed - indexed for MEDLINE]

[View Full Text](#)

- 10 Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.

Hare TR, Gardell SJ.

*Thromb Haemost*. 1992 Aug;3.68(2):165-9.

PMID: 1412162 [PubMed - indexed for MEDLINE]

[View Full Text](#)

Items 1 - 10 of 10

One page.

Display

Summary

Show

20

Sort By

Send to

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)